News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
OncoArendi Therapeutics expands the therapeutic potential of its Chitinase Platform
13 October 2020
OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients
11 September 2020
OncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01
10 September 2020
Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.
9 September 2020
A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship
13 May 2020